Floatz logo

Autologous Dendritic Cell-Adenovirus Ccl21 Vaccine

Cutaneous Melanoma

H. Lee Moffitt Cancer Center and Research InstitutevaccinePhase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

152 Active assets in the Cutaneous Melanoma cohort.

Asset / SponsorPhaseRating
Alpha-Interferon
MIPO Clinic
Phase 3BBB
DACARBAZINE
Linnaeus Therapeutics, Inc.
Phase 3BBB
TIL
City of Hope Medical Center
Phase 2BBB
Tyrosinase Peptide
University of Southern California
Phase 3BBB
CIS-DIAMMINEDICHLOROPLATINUM II
MIPO Clinic
Phase 3BBB

View all 50 →

Same molecule, other indications

Autologous Dendritic Cell-Adenovirus Ccl21 Vaccine is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
lung cancerDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →